Assessment of Extended-Release Opioid Analgesics for the Treatment of Chronic Pain

REFERENCES

• US Census Bureau. Preliminary annual estimates of the resident population for the United States, regions, states, and Puerto Rico: April 1, 2000 to July 1, 2010 (NST-PEST2010–01). 2002 estimates. Available at: http://www. census.gov/popest/research/eval-estimates/NST-PEST2010–01.xls. Accessed May 8, 2012.
   Google Scholar
• National Center for Health Statistics. Health, United States, 2006. With Chartbook on Trends in the Health of Americans. Hyattsville, MD: National Center for Health Statistics; 2006.
   Google Scholar
• Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Washington, DC: The National Academies Press; 2011.
   Google Scholar
• Narayana A, Brook RA. A healthcare claims database analysis to estimate the prevalence of chronic opioid use in adult patients in the United States. Presented at the 25th Annual Meeting of the American Academy of Pain Medicine; January 28–31, 2009; Honolulu, HI. Pain Med. 2009;10(1): abstract 278.
   Google Scholar
• Chou R, Fanciullo GJ, Fine PG, Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10:113–130.
   PubMed Web of Science ®Google Scholar
• Chou R, Qaseem A, Snow V, Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med. 2007;147:478–491.
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Boger RH, Budd K, Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8:287–313.
   PubMedGoogle Scholar
• Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy. 2004;24:468–476.
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage. 2002;23:292–300.
   PubMed Web of Science ®Google Scholar
• Adler L, McDonald C, O'Brien C, Wilson M. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J Rheumatol. 2002;29:2196–2199.
   PubMed Web of Science ®Google Scholar
• Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. J Pain Symptom Manage. 2005;29: 80–90.
   PubMed Web of Science ®Google Scholar
• Moore KT, St-Fleur D, Marricco NC, Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers. J Opioid Manag. 2010;6:351–358.
   PubMedGoogle Scholar
• McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8: 181–186.
   PubMedGoogle Scholar
• Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009;9:468–479.
   PubMed Web of Science ®Google Scholar
• Caldwell JR. Avinza—24-h sustained-release oral morphine therapy. Expert Opin Pharmacother. 2004;5:469–472.
   PubMed Web of Science ®Google Scholar
• Mystakidou K, Clark AJ, Fischer J, Lam A, Pappert K, Richarz U. Treatment of chronic pain by long-acting opioids and the effects on sleep. Pain Pract. 2011;11:282–289.
   PubMedGoogle Scholar
• Brennan MJ, Lieberman JA 3rd. Sleep disturbances in patients with chronic pain: effectively managing opioid analgesia to improve outcomes. Curr Med Res Opin. 2009;25:1045–1055.
   PubMed Web of Science ®Google Scholar
• Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med. 2009;10(Suppl 2):S79–S88.
   PubMedGoogle Scholar
• Gourlay DL, Heit HA. Universal precautions revisited: managing the inherited pain patient. Pain Med. 2009;10(Suppl 2):S115–S123.
   Google Scholar
• Pergolizzi JV, Taylor R, Raffa RB. Extended-release formulations of tramadol in the treatment of chronic pain. Expert Opin Pharmacother. 2011;12:1757–1768.
   PubMed Web of Science ®Google Scholar
• Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol. 2007;7:2.
   PubMedGoogle Scholar
• Sathyan G, Sivakumar K, Thipphawong J. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence of alcohol. Curr Med Res Opin. 2008;24:297–305.
   PubMed Web of Science ®Google Scholar
• Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27: 417–433.
   PubMed Web of Science ®Google Scholar
• Smith HS. Opioid metabolism. Mayo Clin Proc. 2009; 84:613–624.
   PubMed Web of Science ®Google Scholar
• Duragesic (fentanyl transdermal system) [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2009.
   Google Scholar
• OxyContin (oxycodone hydrochloride controlled-release) tablets CII [package insert]. Stamford, CT: Purdue Pharma L.P.; 2011.
   Google Scholar
• Ultram ER (tramadol hydrochloride) [package insert]. Raritan, NJ: Ortho-McNeil; 2009.
   Google Scholar
• Vicodin (hydrocodone bitartrate and acetaminophen tablets). North Chicago, IL: Abbott Laboratories; 2011.
   Google Scholar
• Methadone hydrochloride tablets [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc.; 2009.
   Google Scholar
• Exalgo (hydromorphone HCl) extended-release tablets, CII [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc.; 2012.
   Google Scholar
• Opana ER (oxymorphone hydrochloride) extended-release tablets [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc.; 2012.
   Google Scholar
• Avinza (morphine sulfate extended-release capsules) [package insert]. Bristol, TN: King Pharmaceuticals, Inc.; 2008.
   Google Scholar
• Parsells Kelly J, Cook SF, Kaufman DW, Anderson T, Rosenberg L, Mitchell AA. Prevalence and characteristics of opioid use in the US adult population. Pain. 2008;138: 507–513.
   PubMed Web of Science ®Google Scholar
• Governale L. Outpatient prescription opioid utilization in the US, year 2000–2009. US Food and Drug Administration. 2010. Available at: http://www.fda.gov/downloads/Advisory Committess/CommittessMeetingMaterials/Drugs/DrugSafety andRiskManagementAdvisoryCommittee/UCM220950.pdf. Accessed May 27, 2011.
   Google Scholar
• Joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics. July 22–23, 2010; Adelphi, MD.
   Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention, Office of Public Preparedness and Response. Opioid analgesics: the epidemiology of misuse and advice on prescribing. August 17, 2010. Available at: http://emergency.cdc.gov/coca/ppt/08_17_10_Opioid_FINAL. pdf. Accessed May 11, 2012.
   Google Scholar
• Katz NP, Adams EH, Chilcoat H, Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23:648–660.
   PubMed Web of Science ®Google Scholar
• McCarberg BH. Pain management in primary care: strategies to mitigate opioid misuse, abuse, and diversion. Postgrad Med. 2011;123:119–130.
   PubMed Web of Science ®Google Scholar
• Haanpaa ML, Backonja MM, Bennett MI, Assessment of neuropathic pain in primary care. Am J Med. 2009;122:S13–S21.
   PubMed Web of Science ®Google Scholar
• Khouzam RH. Chronic pain and its management in primary care. South Med J. 2000;93:946–952; quiz 953.
   PubMed Web of Science ®Google Scholar
• McCarberg BH, Adler JA. Updates on managing acute and chronic pain in primary care practice—optimizing pain reduction, minimizing adverse events. JAAPA. 2008;(Suppl Pain):1–13.
   Google Scholar
• Gagnon AM, Kahan M, Srivastava A. Opioid use and abuse: is there a problem? Clin J Pain. 2007;23:661–662.
   PubMed Web of Science ®Google Scholar
• Touchet BK, Yates WR, Coon KA. Opioid contract use is associated with physician training level and practice specialty. J Opioid Manag. 2005;1:195–200.
   PubMedGoogle Scholar
• Drug Abuse Warning Network. Selected Tables: National Estimates, Drug-Related Emergency Department Visits for 2004–09. Available at: https://dawninfo.samhsa.gov/data/ default.asp?met=All. Accessed April 26, 2011.
   Google Scholar
• US Department of Health and Human Services, Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. July 2010. Available at: http:// www.cdc.gov/HomeandRecreationalSafety/pdf/poision-issue-brief.pdf. Accessed May 11, 2012.
   Google Scholar
• Walsh SL, Nuzzo PA, Lofwall MR, Holtman JR Jr. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend. 2008;98:191–202.
   PubMed Web of Science ®Google Scholar
• Marsch LA, Bickel WK, Badger GJ, Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001;299:1056–1065.
   PubMed Web of Science ®Google Scholar
• Comer SD, Ashworth JB, Sullivan MA, Vosburg SK, Saccone PA, Foltin RW. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5:203–212.
   PubMedGoogle Scholar
• Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18:255–263.
   PubMed Web of Science ®Google Scholar
• Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12:618–631.
   PubMed Web of Science ®Google Scholar
• Shram MJ, Sathyan G, Khanna S, Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30:25–33.
   PubMed Web of Science ®Google Scholar
• Katz N, Fernandez K, Chang A, Benoit C, Butler SF. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain. 2008;24:528–535.
   PubMed Web of Science ®Google Scholar
• Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20:5–13.
   PubMedGoogle Scholar
• Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10:11–18.
   PubMedGoogle Scholar
• Embeda (morphine sulfate and naltrexone hydrochloride) [package insert]. Bristol, TN: King Pharmaceuticals; 2012.
   Google Scholar
• Kadian (morphine sulfate extended-release) capsules [package insert]. Morristown, NJ: Actavis Elizabeth LLC; 2012.
   Google Scholar
• MS Contin (morphine sulfate controlled-release) tablets [package insert]. Stamford, CT: Purdue Pharma L.P.; 2009.
   Google Scholar
• Oramorph SR (morphine sulfate) sustained release tablets [package insert]. Newport, KY: Xanodyne Pharmaceticals, Inc.; 2006.
   Google Scholar
• Butrans (buprenorphine) transdermal system for transdermal administration [prescribing information]. Stamford, CT: Purdue Pharma L.P.; 2010.
   Google Scholar
• Nucynta ER (tapentadol) extended-release oral tablets [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2011.
   Google Scholar
• Fentanyl transdermal system [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2009.
   Google Scholar
• Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26:1505–1518.
   PubMed Web of Science ®Google Scholar
• Turgeon J, Groning R, Sathyan G, Thipphawong J, Richarz U. The pharmacokinetics of a long-acting OROS hydromorphone formulation. Expert Opin Drug Deliv. 2010;7:137–144.
   PubMed Web of Science ®Google Scholar
• Gupta S, Sathyan G. Providing constant analgesia with OROS hydromorphone. J Pain Symptom Manage. 2007;33(2 Suppl):S19–S24.
   Web of Science ®Google Scholar
• Angst MS, Drover DR, Lotsch J, Pharmacodynamics of orally administered sustained- release hydromorphone in humans. Anesthesiology. 2001;94:63–73.
   PubMed Web of Science ®Google Scholar
• Richarz U, Vandenbossche J, Moore K. Characterization of the steady-state pharmacokinetic profile of once-daily hydromorphone ER (OROS hydromorphone) versus IR hydromorphone in healthy volunteers [abstract]. J Pain. 2011;12(4 Suppl): P60.
   Google Scholar
• Pande P, Hines J, Brogan A. Tamper-resistant properties of once-daily hydromorphone ER (OROS hydromorphone) [abstract]. J Pain. 2011;12(4 Suppl):P58.
   Google Scholar
• OxyContin (oxycodone hydrochloride controlled-release) tablets CII [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010. [Old formulation; no longer available].
   Google Scholar
• Jayawant SS, Balkrishnan R. The controversy surrounding OxyContin abuse: issues and solutions. Ther Clin Risk Manag. 2005;1:77–82.
   PubMedGoogle Scholar
• US Department of Health and Human Services, US Food and Drug Administration. FDA approves new formulation for OxyContin [news release]; April 5, 2010. Available at: http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm207480.htm. Updated April 7, 2010. Accessed April 17, 2012.
   Google Scholar
• Horn JR, Hansten PD. Get to know an enzyme: CYP3A4. Pharmacy Times. 2008. Published online September 1, 2008. http://pharmacytimes.com/publications/issue/2008/2008-09-8687. Accessed February 11, 2013.
   Google Scholar
• Webster LR, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. J Pain. 2010;11:602–611.
   PubMed Web of Science ®Google Scholar
• Black R, Coplan P, Cassidy T, Effects of reformulated OxyContin® among patients assessed for substance abuse treatment in the NAVIPPRO sentinel surveillance network [abstract]. J Pain. 2012;13(4 Suppl):S58.
   Google Scholar
• Benedek IH, Jobes J, Xiang Q, Fiske WD. Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release. Drug Des Dev Ther. 2011;5:455–463.
   PubMed Web of Science ®Google Scholar
• Bartholomaeus JH, Arkenau-Marić E, Galia E. Opioid extended-release tablets with improved tamper-resistant properties. Expert Opin Drug Deliv. 2012;9:879–891.
   PubMed Web of Science ®Google Scholar
• Fiske WD, Jobes J, Xiang Q, Chang S-C, Benedek IH. The effects of ethanol on the bioavailability of oxymorphone extended-release tablets and oxymorphone crush-resistant extended-release tablets. J Pain. 2012;13:90–99.
   PubMed Web of Science ®Google Scholar
• Miller DA, Dinunzio JC, Williams RO 3rd. Advanced formulation design: improving drug therapies for the management of severe and chronic pain. Drug Dev Ind Pharm. 2008;34:117–133.
   PubMed Web of Science ®Google Scholar
• Johnson FK, Ciric S, Boudriau S, Kisicki JC, Stauffer J. The relative bioavailability of morphine sulfate and naltrexone hydrochloride extended release capsules (EMBEDA) and an extended release morphine sulfate capsule formulation (KADIAN) in healthy adults under fasting conditions. Am J Ther. 2011;18:2–8.
   PubMed Web of Science ®Google Scholar
• Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. J Pain. 2010;11:303–311.
   PubMed Web of Science ®Google Scholar
• Johnson F, Wagner G, Sun S, Stauffer J. Effect of concomitant ingestion of alcohol on the in vivo pharmacokinetics of KADIAN (morphine sulfate extended-release) capsules. J Pain. 2008;9:330–336.
   PubMed Web of Science ®Google Scholar
• Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs. 2010;70:1657–1675.
   PubMed Web of Science ®Google Scholar
• Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: a randomized, double-blind, placebo-controlled, crossover study. Clin Drug Invest. 2009;29:777–790.
   PubMed Web of Science ®Google Scholar
• Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. Acute opioid withdrawal precipitated by ingestion of crushed Embeda (morphine extended release with sequestered naltrexone): case report and the focused review of the literature. J Opioid Manag. 2010;6:300–303.
   PubMedGoogle Scholar
• Plosker GL. Buprenorphine 5, 10 and 20 μ/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs. 2011;71:2491–2509.
   PubMed Web of Science ®Google Scholar
• Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4:28–41.
   PubMedGoogle Scholar
• Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5:230–241.
   PubMedGoogle Scholar
• Kuhlman JJ, McCaulley R, Valouch TJ, Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J Anal Toxicol. 2003;27:499–504.
   PubMed Web of Science ®Google Scholar
• Lilleng PK, Mehlum LI, Bachs L, Deaths after intravenous misuse of transdermal fentanyl. J Forensic Sci. 2004;49:1–3.
   Web of Science ®Google Scholar
• Reeves MD, Ginifer CJ. Fatal intravenous misuse of transdermal fentanyl. Med J Aust. 2002;177:552–553.
   PubMed Web of Science ®Google Scholar
• Marier J-F, Lor M, Potvin D, DiMarco M, Morelli G, Sædder EA. Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol. 2006;46: 642–653.
   PubMed Web of Science ®Google Scholar
• Sellers EM, Schuller R, Romach MK, Relative abuse potential of opioid formulations in Canada: a structured field study. J Opioid Manag. 2006;2:219–227.
   PubMedGoogle Scholar
• Prosser JM, Jones BE, Nelson L. Complications of oral exposure to fentanyl transdermal delivery system patches. J Med Toxicol. 2010;6:443–447.
   PubMedGoogle Scholar
• Freynhagen R, von Giesen HJ, Busche P, Sabatowski R, Konrad C, Grond S. Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: a prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage. 2005;30:289–297.
   PubMed Web of Science ®Google Scholar
• Sathyan G, Guo C, Sivakumar K, Gidwano S, Gupta S. Evaluation of the bioequivalence of two transdermal fentanyl systems following single and repeat applications. Curr Med Res Opin. 2005;21:1961–1968.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Risk evaluation and mitigation strategy (REMS) for extended-release and long-acting opioids. Available at: http://www.fda.gov/drugs/drugsafety/ informationbydrugclass/ucm163647.htm. Updated July 16, 2012. Accessed July 26, 2012.
   Google Scholar
• Craig DS. The Food and Drug Administration risk evaluation and mitigation strategy. J Pain Palliat Care Pharmacother. 2010;24:145–148.
   PubMedGoogle Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Questions and answers: FDA approves a risk evaluation and mitigation strategy (REMS) for extended-release and long-acting (ER/LA) opioid analgesics. Available at: http://www.fda.gov/Drugs/DrugSafety/Information byDrugClass/ucm309742.htm. Updated July 14, 2012. Accessed July 26, 2012.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics. Available at: http://www.fda.gov/downloads/Drugs/ DrugSafety/InformationbyDrugClass/ucm277916.pdf. Updated July 9, 2012. Accessed July 26, 2012.
   Google Scholar
• Medical Board of California. New laws related to continuing medical education. Available at: http://www.mbc.ca.gov/ licensee/continuing_education_laws.html. Accessed May 10, 2012.
   Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration. Post-approval REMS notification. 2011. Available at: http://www.fda.gov/downloads/Drugs/ DrugSafety/InformationByDrugClass/UCM251595.pdf. Accessed May 10, 2012.
   Google Scholar